<DOC>
	<DOCNO>NCT02876900</DOCNO>
	<brief_summary>This study design evaluate efficacy safety HP-3070 compare placebo transdermal patch subject diagnose schizophrenia .</brief_summary>
	<brief_title>Study Assess Efficacy Safety HP3070 Subjects Diagnosed With Schizophrenia .</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , in-patient , safety , efficacy study evaluate HP-3070 treatment schizophrenia . This study design evaluate efficacy safety HP-3070 compare placebo transdermal patch subject diagnose schizophrenia , acute exacerbation ass impact covariates asenapine exposure deliver patch formulation , use population-based approach .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Current diagnosis schizophrenia . Subject PANSS total score â‰¥80 , AND score 4 least 2 follow PANSS item Screening Baseline : conceptual disorganization delusion ; hallucinatory behavior ; unusual thought content . Subjects must able wear transdermal patch 24 hour . Subject diagnose schizophrenia le 6 month prior Screening Visit . Subject receive within 90 day Screening Visit : electroconvulsive therapy ; transcranial magnetic stimulation ; vagal nerve stimulation ; brain stimulation treatment Subject experience acute depressive symptom within 30 day prior Screening Visit require treatment antidepressant , determine Investigator . Currently take clozapine treatment schizophrenia . Has hypothyroidism hyperthyroidism . Subject currently treat insulin diabetes . Subject epilepsy history seizure . Positive urine pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>